Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | -6.37% | -6.75% | -20.34% |
Financials (USD)
Sales 2024 * | 3.45M | Sales 2025 * | 9.13M | Capitalization | 87.03M |
---|---|---|---|---|---|
Net income 2024 * | -97M | Net income 2025 * | -83M | EV / Sales 2024 * | 61.5 x |
Net Debt 2024 * | 125M | Net Debt 2025 * | 115M | EV / Sales 2025 * | 22.1 x |
P/E ratio 2024 * |
-0.85
x | P/E ratio 2025 * |
-1.34
x | Employees | 74 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.61% |
Latest transcript on BioXcel Therapeutics, Inc.
1 day | -6.37% | ||
1 week | -6.75% | ||
Current month | -6.75% | ||
1 month | -11.65% | ||
3 months | -37.83% | ||
6 months | -51.45% | ||
Current year | -20.34% |
Managers | Title | Age | Since |
---|---|---|---|
Vimal Mehta
FOU | Founder | 63 | 17-03-28 |
Director of Finance/CFO | 66 | 17-09-30 | |
Frank Yocca
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Miller
BRD | Director/Board Member | 67 | 22-06-30 |
Peter Mueller
CHM | Chairman | 68 | 17-03-31 |
Sandeep Laumas
BRD | Director/Board Member | 56 | 17-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | +8.42% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 2.35 | -6.37% | 862,502 |
24-05-06 | 2.51 | -2.33% | 377,555 |
24-05-03 | 2.57 | +0.39% | 147,562 |
24-05-02 | 2.56 | +0.79% | 206,748 |
24-05-01 | 2.54 | +0.79% | 210,560 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.34% | 87.03M | |
+10.44% | 107B | |
+0.82% | 106B | |
+7.69% | 23.47B | |
-13.89% | 21.9B | |
-6.64% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- BTAI Stock